ITMN Denied FDA Approval For Drug Pirfenidone To Treat Pulmonary Fibrosis

InterMune Inc, ITMN, was refused approval for their drug that treats lung scarring by the Food and Drug Administration. The FDA asked ITMN to produce a new clinical trial that will prove the drug actually works in treating lung scarring. This announcement caused ITMN’s share to fall 80%.